🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07306390
Starting soon Observational

Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)

NCT07306390 · tracked via the Priya Life Science China tracker
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Observational
Started
2026-07-01
Last updated
2026-06-09

Condition(s) studied

Colon CancerRectal Cancer

Study summary

The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:

* What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?
* Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 80 years * Pathologically confirmed adenocarcinoma of the colon or rectum * Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol * No distant metastasis or distant metastasis within 6 months after surgery * No history of other malignant tumors or severe systemic diseases * No immune diseases or inflammatory bowel diseases * Non-emergency surgery * With complete clinicopathological and follow-up data Exclusion Criteria: * Pathologically confirmed benign tumors or non-adenocarcinoma malignancies * Underwent local excision or palliative resection * Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol * With distant metastasis or distant metastasis within 6 months after surgery * Dual or multiple primary colorectal cancers or concurrent other malignant tumors * Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease * Underwent emergency surgery * Had incomplete clinicopathological or follow-up data

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Beijing China

More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07306390 on ClinicalTrials.gov ↗ ← All trials in China